# A Study of Cusatuzumab Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia Who Are Not Candidates for Intensive Chemotherapy

Source: https://onco.cc/trials/nct04023526/  
OnCo record `nct04023526` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Azacitidine and Cusatuzumab in acute myeloid leukaemia, run by OncoVerity, Inc., active and no longer recruiting.

## Summary

A Study of Cusatuzumab Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia Who Are Not Candidates for Intensive Chemotherapy is a phase 2 interventional study registered as NCT04023526 by OncoVerity, Inc., with 103 participants enrolled, started 2019-07-29 and due to reach its primary completion in 2023-08-15. Interventions recorded: Azacitidine and Cusatuzumab. Results have been posted on the registry.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04023526
- Phase: 2
- Setting: A Phase 2 Study of Cusatuzumab Plus Azacitidine in Patients With Newly Diagnosed Acute Myeloid Leukemia Who Are Not Candidates for Intensive Chemotherapy
- Sponsor: OncoVerity, Inc.
- Enrolled: 103

## Sources

- ClinicalTrials.gov NCT04023526: https://clinicaltrials.gov/study/NCT04023526

## Connected records

- cancers: [Acute myeloid leukaemia](https://onco.cc/cancers/aml/)
- drugs: [Azacitidine](https://onco.cc/drugs/azacitidine/), [Cusatuzumab](https://onco.cc/drugs/cusatuzumab/)
- companies: [argenx](https://onco.cc/companies/argenx/), [Johnson & Johnson](https://onco.cc/companies/johnson-johnson/), [OncoVerity](https://onco.cc/companies/oncoverity/)

---
JSON: https://onco.cc/api/v1/entities/nct04023526.json